Comprehensive BRCA mutation analysis in the Greek population. Experience from a single clinical diagnostic center.

[1]  K. Kyriacou,et al.  BRCA1 and BRCA2 mutation testing in Cyprus; a population based study , 2017, Clinical genetics.

[2]  F. Fostira,et al.  Haplotype analysis reveals that the recurrent BRCA1 deletion of exons 23 and 24 is a Greek founder mutation , 2017, Clinical genetics.

[3]  Ricardo Villamarín-Salomón,et al.  ClinVar: public archive of interpretations of clinically relevant variants , 2015, Nucleic Acids Res..

[4]  L. Walker,et al.  Meeting the challenges of interpreting variants of unknown clinical significance in BRCA testing. , 2015, The New Zealand medical journal.

[5]  R. Gibbs,et al.  Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. , 2015, Human molecular genetics.

[6]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[7]  Julie O. Culver,et al.  Variants of uncertain significance in BRCA testing: evaluation of surgical decisions, risk perception, and cancer distress , 2013, Clinical genetics.

[8]  Quinten Waisfisz,et al.  Best Practice Guidelines for the Use of Next‐Generation Sequencing Applications in Genome Diagnostics: A National Collaborative Study of Dutch Genome Diagnostic Laboratories , 2013, Human mutation.

[9]  A. Kiss,et al.  Variants of unknown significance in BRCA testing: impact on risk perception, worry, prevention and counseling. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  J. Vermeesch,et al.  Molecular analysis of the breast cancer genes BRCA1 and BRCA2 using amplicon-based massive parallel pyrosequencing. , 2012, The Journal of molecular diagnostics : JMD.

[11]  Puay Hoon Tan,et al.  Development of a next-generation sequencing method for BRCA mutation screening: a comparison between a high-throughput and a benchtop platform. , 2012, The Journal of molecular diagnostics : JMD.

[12]  K. Offit,et al.  Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families , 2010, Breast Cancer Research and Treatment.

[13]  M. Metzker.  Sequencing technologies — the next generation , 2010, Nature Reviews Genetics.

[14]  C. Béroud,et al.  Human Splicing Finder: an online bioinformatics tool to predict splicing signals , 2009, Nucleic acids research.

[15]  D. Yannoukakos,et al.  Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients , 2008, Breast Cancer Research and Treatment.

[16]  D. Yannoukakos,et al.  Novel genomic rearrangements in the BRCA1 gene detected in Greek breast/ovarian cancer patients. , 2007, European journal of cancer.

[17]  A. Gerdes,et al.  Low frequency of large genomic rearrangements of BRCA1 and BRCA2 in western Denmark. , 2006, Cancer genetics and cytogenetics.

[18]  L. Chieco‐Bianchi,et al.  Large genomic deletions inactivate the BRCA2 gene in breast cancer families , 2005, Journal of Medical Genetics.

[19]  James R. Knight,et al.  Genome sequencing in microfabricated high-density picolitre reactors , 2005, Nature.

[20]  J. Kirk,et al.  Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families , 2005, Journal of Medical Genetics.

[21]  K. Kyriacou,et al.  Characterization of a novel large deletion and single point mutations in the BRCA1 gene in a Greek cohort of families with suspected hereditary breast cancer , 2004, BMC Cancer.

[22]  C. Bartram,et al.  Twenty‐three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany , 2003, Human mutation.

[23]  L. Chieco‐Bianchi,et al.  Genomic rearrangements account for more than one-third of the BRCA1 mutations in northern Italian breast/ovarian cancer families. , 2003, Human molecular genetics.

[24]  C. Deng,et al.  Roles of BRCA1 in DNA damage repair: a link between development and cancer. , 2003, Human molecular genetics.

[25]  L. V. van't Veer,et al.  Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. , 2003, Cancer research.

[26]  Dominique Stoppa-Lyonnet,et al.  Rapid detection of novel BRCA1 rearrangements in high‐risk breast‐ovarian cancer families using multiplex PCR of short fluorescent fragments , 2002, Human mutation.

[27]  A. Whittemore,et al.  Comparison of DNA‐ and RNA‐Based Methods for Detection of Truncating BRCA1 Mutations , 2002, Human mutation.

[28]  D. Zwijnenburg,et al.  Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. , 2002, Nucleic acids research.

[29]  A. Venkitaraman,et al.  Functions of BRCA1 and BRCA2 in the biological response to DNA damage. , 2001, Journal of cell science.

[30]  K. Shiraki,et al.  Breast cancer genetics: what we know and what we need , 2001, Nature Medicine.

[31]  M. Stratton,et al.  The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators. , 2000, Cancer research.

[32]  Csilla Szabo,et al.  The Breast Cancer Information Core: Database design, structure, and scope , 2000, Human mutation.

[33]  S. Neuhausen.  Ethnic differences in cancer risk resulting from genetic variation , 1999, Cancer.

[34]  E. Gross,et al.  A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC , 1999, Human Genetics.

[35]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[36]  M. Khoury,et al.  Increased risk for familial ovarian cancer among Jewish women: A population‐based case‐control study , 1998, Genetic epidemiology.

[37]  Peter Devilee,et al.  BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients , 1997, Nature Genetics.

[38]  M. King,et al.  Population genetics of BRCA1 and BRCA2. , 1997, American journal of human genetics.

[39]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.

[40]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.